Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome
Article 2018 en
Authors
YA
Yo Han Ahn
SK
Seong Heon Kim
KH
Kyoung Hee Han
Abstract
1 min read
RTX administration was safe and effective in patients with difficult-to-treat NS. One or 2 doses of RTX may be sufficient to deplete B cells and achieve better control of pediatric NS.
Yo Han Ahn, Hee Gyung Kang, Seong Heon Kim, Kyoung Hee Han, Hee Yeon Cho, Jae Il Shin, Min Hyun Cho, Young Seo Park, Su Yung Kim, Seung Joo Lee, Hae Il Cheong, Il Soo Ha
Piero Ruggenenti, Barbara Ruggiero, Paolo Cravedi, Marina Vivarelli, Laura Massella, Maddalena Marasà, Antonietta Chianca, Nadia Rubis, Bogdan Ene‐Iordache, Michael Rudnicki, Rosa Maria Pollastro, Giovambattista Capasso, Antonio Pisani, Marco Pennesi, Francesco Emma, Giuseppe Remuzzi
Discussion(0)
No comments yet. Be the first to comment.